Prostate Cancer

Latest News

February 18th 2024

Dr Jun Gong: Improved Access Closes the Gaps Between Black, White Men With Prostate Cancer

By Laura Joszt, MA

September 27th 2023

Surgery, Radiation for PCa Show Equal Efficacy in Candidates for Renal Transplantation

September 22nd 2023

Racial Differences in Chemokine Expression May Contribute to Prostate Cancer Disparities

September 16th 2023

Cabozantinib Plus Atezolizumab Significantly Improves PFS in Metastatic CRPC

By Russ Conroy

September 14th 2023

Expert Panel Addresses Prostate Cancer Misconceptions, Importance of Screening

Video Interviews

April 14th 2023

Dr Ryan Huey: Expansion of Patient Support, Care Key to Improve Value-Based Oncology

April 8th 2023

Dr Mike Lattanzi: Precision Oncology Options and Increasing Rates of Prostate Cancer

September 26th 2022

Dr William Oh Discusses Goals of Prostate Cancer Awareness Month

April 13th 2022

CVD Risk in Prostate Cancer: Future Directions in Care

April 6th 2022

Multidisciplinary Care in Prostate Cancer and CVD Management

April 6th 2022

CVD Risk in Prostate Cancer: Quality Measures and Coverage Policy

March 30th 2022

What Evidence Is Needed to Further Define CVD Risk in Prostate Cancer?

March 30th 2022

Factors in Evaluating Therapy for Prostate Cancer

March 23rd 2022

CVD in Prostate Cancer: Risk-Bearing Practices and Alternative Payment Models

March 23rd 2022

Impact of CVD Risk on Cost of Care in Prostate Cancer

More News

Prostate cancer | Image credit: freshidea - stock.adobe.com

September 8th 2023

Adaptive SBRT May Reduce GU/GI Toxicity Risk in Prostate Cancer

A meta-analysis found that the use of magnetic resonance–guided daily adaptive stereotactic body radiotherapy (SBRT) correlated with fewer acute grade 2 or higher gastrointestinal (GI) or genitourinary (GU) toxicities compared with CT-guided non-adaptive SBRT in patients with prostate cancer.

Double Helix purple

September 6th 2023

Genetic Alterations Discovered in Hispanic Men With Prostate Cancer

In an exploratory analysis, Hispanic men with primary and metastatic prostate cancer exhibited higher frequencies of certain altered genes compared to non-Hispanic men.

While Prognostic, BCR May Not Be a Strong Surrogate End Point for Prostate Cancer Survival

August 31st 2023

While Prognostic, BCR May Not Be a Strong Surrogate End Point for Prostate Cancer Survival

Measuring biochemical recurrence (BCR) as a surrogate marker produces unreliable results as a primary end point for overall survival of patients with localized prostate cancer, a study found.

MRI Screening Provides Advantages for Detecting Clinically Significant Prostate Cancer

August 25th 2023

MRI Screening Provides Advantages for Detecting Clinically Significant Prostate Cancer

MRI screening shows promise for predicting clinically significant prostate cancer (PCa) early on and independently of prostate-specific antigen (PSA) assessment.

FDA Approved

August 19th 2023

FDA Approves FoundationOne CDx as Companion Diagnostic for Niraparib/Abiraterone in mCRPC

The FDA companion diagnostic designation for FoundationOne CDx may improve access to niraparib/abiraterone acetate for eligible patients with metastatic castration-resistant prostate cancer (mCRPC) harboring a BRCA mutation.

Doctor and Patient Discussing Prostate Cancer

August 19th 2023

Study Validates PSA-Based Recurrence Definitions for Prostate Cancer Prognostication

Researchers determined that the Huber et al. criteria regarding prostate-specific antigen (PSA) levels may more accurately predict the need for additional treatment or the possibility of treatment failure compared with other PSA-based definitions.

Flotufolastat F 18 Injection for Prostate Cancer Added to NCCN Guidelines

August 12th 2023

Flotufolastat F 18 Injection for Prostate Cancer Added to NCCN Guidelines

Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.

Prostate Cancer Detection

August 11th 2023

Novel Biomarker Panel Accurately Predicts Prostate Cancer Outcomes

New biomarker technology shows promising results for predicting the prognosis of patients with prostate cancer after radical prostatectomy.

AI graphic

August 5th 2023

AI Model May Define Margins and Help Identify Risk in Prostate Cancer

Nicholas Wrigley

Investigators of a retrospective study report that an AI deep learning model may also predict negative margin probabilities better than conventional modalities.

Image of paper figures representing skin tones

August 3rd 2023

Equitable Care Access May Reduce Outcome Disparities in Advanced Prostate Cancer

A recent study suggests that a lack of equitable access to care contributes to known disparities in outcomes between Black and White patients with advanced prostate cancer.

Consultation with doctor for prostate cancer

July 31st 2023

Study Finds Link Between Baseline Uric Acid Levels and Prostate Cancer Prognosis

Researchers linking uric acid (UA) levels to the aggressiveness and progression of prostate cancer believe these findings can be used to study UA influence on prostate cancer–related mortality risk.

Doctor and man discussing prostate

July 26th 2023

Prostate-Specific Antigens Post Salvage Radiotherapy Predict Survival Outcomes of Patients With Recurrent Prostate Cancer

Following prostatectomy in patients with recurrent prostate cancer, researchers analyzed post–salvage radiotherapy prostate-specific antigen (PSA) values and the percentages of PSA decline to anticipate patient survival rates.

Older White patient speaking with Black doctor

July 22nd 2023

Localized Therapy Improves Prognosis in Some Men With Metastatic Prostate Cancer

Forms of localized treatment have potential to positively impact the survival rate and prognosis of men diagnosed with certain forms of metastatic prostate cancer.

Cell Phone With Telehealth App

July 19th 2023

Study Examines Telehealth Use Disparities Among Prostate Cancer Survivors

Most prostate cancer survivors surveyed reported feeling that telehealth cannot fully replace in-person visits, with perceptions varying significantly based on education level.

Prostate Cancer

July 14th 2023

Olaparib Increases Radioligand Activity in mCRPC, Early Findings Suggest

Brittany Lovely

Enhanced antitumor activity was seen with the addition of the PARP inhibitor olaparib to the radioligand lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration-resistant prostate cancer.

Man in Hospital Bed

July 12th 2023

Many Patients With Prostate Cancer May Face Treatment-Related Financial Toxicity

Patients with metastatic prostate cancer who face high financial toxicity resulting from treatment may cope in ways that impact overall quality of life, according to a recent study.

Artificial intelligence model graphic

July 6th 2023

Novel AI Model Predicts ADT Benefit in Patients With Prostate Cancer

A predictive artificial intelligence (AI) biomarker of androgen deprivation therapy (ADT) benefit in prostate cancer was validated in a recent study published in NEJM Evidence.

Study Suggests Cardiorespiratory Fitness Impacts Cancer Risk in Men

June 30th 2023

Study Suggests Cardiorespiratory Fitness Impacts Cancer Risk in Men

The study aimed to assess whether CRF was associated with prostate, colon, and lung cancer incidence and mortality among men in Sweden.

FDA Approves Talazoparib Plus Enzalutamide for mCRPC With HRR Gene Mutations

June 21st 2023

FDA Approves Talazoparib Plus Enzalutamide for mCRPC With HRR Gene Mutations

Talazoparib in combination with enzalutamide showed a 55% reduction in the risk of disease progression or death for patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene mutations in the phase 3 TALAPRO-2 trial.

IMRT for Prostate Cancer Not Associated With Increased Risk of Second Primary Cancers, Study Finds

June 16th 2023

IMRT for Prostate Cancer Not Associated With Increased Risk of Second Primary Cancers, Study Finds

There was no difference in second primary cancer risk among older adult male patients treated with intensity-modulated radiotherapy (IMRT) vs 3-dimensional conformal radiation therapy for prostate cancer.

Patients With BRCA-Mutated mCRPC Show Worse Outcomes vs Non-BRCA HRR mCRPC

June 10th 2023

Patients With BRCA-Mutated mCRPC Show Worse Outcomes vs Non-BRCA HRR mCRPC

An analysis of patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) deficiency mutations showed that patients with BRCA mutations had poor outcomes compared with those without BRCA mutations and those with non-BRCA HRR mutations.

Study Finds PSMA-PET May Hold Prognostic Utility in Prostate Cancer

June 9th 2023

Study Finds PSMA-PET May Hold Prognostic Utility in Prostate Cancer

Research presented at the American Society of Clinical Oncology Annual Meeting found prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) to be associated with worse overall survival in prostate cancer without distant metastasis based on conventional imaging.

FDA Approves First Radiohybrid PSMA-Targeted PET Imaging Agent for Prostate Cancer

June 2nd 2023

FDA Approves First Radiohybrid PSMA-Targeted PET Imaging Agent for Prostate Cancer

The FDA has approved flotufolastat F 18 injection for positron emission tomography of prostate-specific membrane antigen–positive lesions in certain men with prostate cancer.

FDA Approves Olaparib Combination to Treat BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

June 1st 2023

FDA Approves Olaparib Combination to Treat BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Olaparib plus abiraterone and prednisone or prednisolone already is approved in the European Union and several other countries.

map of florida

May 24th 2023

Study Identifies Predictors of PSA Screening for Men in Florida

Results are based off of data from the Florida Behavioral Risk Factor Surveillance System.

Bladder and prostate in the doctor's hand, HTA. Prostate cancer, bladder cancer, men's health care. Modern digital medicine in urology: © Tom - stock.adobe.com

May 16th 2023

Low SES Linked With Lower Overall Survival in Early-Onset Prostate Cancer

Researchers suggest socioeconomic status (SES) be considered in prognostic algorithms going forward.

Paper with prostate cancer and light blue ribbon: © Vitalii Vodolazskyi - stock.adobe.com

May 9th 2023

Extended PLND Marginally Reduces Recurrence Risk in High-Risk Patients Undergoing Radical Prostatectomy

Jared Kaltwasser

No benefit was found in low-risk patients who underwent pelvic lymph node dissection (PLND).

Certain Comorbidities May Predict Cardiovascular Event Risk After ADT for Prostate Cancer

May 5th 2023

Certain Comorbidities May Predict Cardiovascular Event Risk After ADT for Prostate Cancer

The presence of certain comorbidities prior to androgen deprivation therapy (ADT) for prostate cancer may be associated with a greater risk of cardiovascular events after starting ADT, recent research found.

Doctor and Patient Talking

May 4th 2023

Patients With Prostate Cancer Most Concerned With ADT Cost, Delivery Method

A cross-sectional survey of patient preferences found that the out-of-pocket cost of treatment was the most impactful attribute for patients when choosing an androgen deprivation therapy (ADTs) for their prostate cancer.

Study Suggests Use of Active Surveillance for Prostate Cancer Is Increasing

April 21st 2023

Study Suggests Use of Active Surveillance for Prostate Cancer Is Increasing

The use of active surveillance for indolent prostate cancer cases continues to rise in the United States, but rates of use are lower in minority groups, low-income groups, and patients in rural areas, a recent study found.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions